Nurix Therapeutics Announces Partial Clinical Hold For NX-2127 Phase 1 Trial
Portfolio Pulse from Benzinga Newsdesk
Nurix Therapeutics, Inc. (NASDAQ:NRIX) announced that the FDA has placed a partial clinical hold on the Phase 1 NX-2127-001 study evaluating NX-2127 in various B-cell malignancies. The hold follows the company's communication to the FDA of its intention to transition to an improved manufacturing process. Nurix's other drug programs are not affected by the NX-2127 manufacturing process improvement.
November 01, 2023 | 9:09 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Nurix Therapeutics' Phase 1 NX-2127-001 study has been partially halted by the FDA due to a transition to an improved manufacturing process. This could potentially delay the study's progress.
The FDA's partial clinical hold on Nurix's Phase 1 study could potentially delay the study's progress and impact the company's timeline for the development and potential approval of NX-2127. This could negatively affect the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100